

# **CERTIFICATE OF ANALYSIS**

Page 1 of 2

1	V-PLEX <sup>®</sup> SARS-CoV-2 Panel 17 Kit K15524-Series, K15525-Series, K15526-Series, K15527-Series; K15528-
	Series; K15529-Series; K15530-Series
Kit Lot Number:	K0082065
<b>Expiration Date</b> :	31 JAN 2024

# **Kit Components:**

Description	Lot Number	Storage Temperature	<b>Expiration Date</b>
SARS-CoV-2 Plate 17	Z0057190	2-8°C	30 NOV 2024
Reference Standard 1	A0080286	$\leq$ -70°C	28 FEB 2026
Serology Control 1.1	A00C0825	≤ -70°C	31 MAR 2027
Serology Control 1.2	A00C0826	≤ -70°C	31 MAR 2027
Serology Control 1.3	A00C0827	≤ -70°C	31 MAR 2027
SULFO-TAG <sup>™</sup> Human ACE2 Protein	D0081760	2-8°C	31 JAN 2024
ACE2 Calibration Reagent	A0080301	2-8°C	31 MAR 2025
SULFO-TAG <sup>™</sup> Anti-Human IgG Antibody	D00V0024	2-8°C	31 AUG 2025
SULFO-TAG <sup>™</sup> Anti-Human IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG <sup>™</sup> Anti-Human IgA Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG <sup>™</sup> Anti-Mouse IgG Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG <sup>™</sup> Anti-Mouse IgM Antibody	Not Kit Specific	2-8°C	See Label
SULFO-TAG <sup>™</sup> Anti-Mouse IgA Antibody	Not Kit Specific	2-8°C	See Label
Diluent 100	Not Kit Specific	2-8°C	See Label
MSD Blocker A Kit	Not Kit Specific	Room Temperature	See Label
MSD GOLD Read Buffer B	Not Kit Specific	Room Temperature	See Label

See product insert regarding which components are provided with each IgG, IgA, IgM, or ACE2 kit.

### **Plate Uniformity Testing Results:**

Parameter	Precision			Uniformity	Signal
Metric	CV of Intra- plate Averages	Average Intra- plate CV	Max Intra- plate CV	Average Uniformity Metric	Average Signal
SARS-CoV-2 Spike	$\leq 18\%$	$\leq 10\%$	≤13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Spike (D614G)	$\leq 18\%$	$\leq 10\%$	≤13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Nucleocapsid	≤18%	$\leq 10\%$	≤13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	≤18%	≤ 10%	≤1 <b>3</b> %	Pass	1,500 - 1,000,000
SARS-CoV-2 Spike (P.1)	$\leq 18\%$	$\leq 10\%$	≤13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Spike (B.1.1.7)	≤18%	$\leq 10\%$	≤13%	Pass	1,500 - 1,000,000
SARS-CoV-2 Spike (B.1.351)	≤18%	$\leq 10\%$	≤13%	Pass	1,500 - 1,000,000
SARS-CoV-2 S1 RBD	≤18%	≤10%	≤13%	Pass	1,500 - 1,000,000



### **CERTIFICATE OF ANALYSIS**

Page 2 of 2

### **Coating Confirmation Testing Results:**

Spot	Description	Result
1	SARS-CoV-2 Spike	Pass
2	SARS-CoV-2 Spike (D614G)	Pass
3	SARS-CoV-2 Nucleocapsid	Pass
4	SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.6; AY.7; AY.14) <b>Alt Seq 1</b>	Pass
7	SARS-CoV-2 Spike (P.1)	Pass
8	SARS-CoV-2 Spike (B.1.1.7)	Pass
9	SARS-CoV-2 Spike (B.1.351)	Pass
10	SARS-CoV-2 S1 RBD	Pass

Note: Alternative S-GENE mutations for Spike of AY.1, AY.2, and B.1.617.2 are listed as "Alt Seq#."

#### **Functional Testing Results:**

Sample Type	Calibrator	Controls		Samples	
Metric	Avg Signal Ratio Test:Reference	Control Recovery	Control Conc. CV	Avg % Difference Test:Reference	Slope Test:Reference
SARS-CoV-2 Spike	50 - 200%	70 - 130%	< 20%	$\pm 25\%$	0.80 - 1.2
SARS-CoV-2 Spike (D614G)	50 - 200%	70 - 130%	< 20%	$\pm 25\%$	0.80 - 1.2
SARS-CoV-2 Nucleocapsid	50 - 200%	70-130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (B.1.617.2; AY.3; AY.5; AY.6; AY.7; AY.14) Alt Seq 1	50 - 200%	70-130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 Spike (P.1)	50 - 200%	70 - 130%	< 20%	$\pm 25\%$	0.80 - 1.2
SARS-CoV-2 Spike (B.1.1.7)	50 - 200%	70 - 130%	< 20%	$\pm 25\%$	0.80 - 1.2
SARS-CoV-2 Spike (B.1.351)	50 - 200%	70-130%	< 20%	± 25%	0.80 - 1.2
SARS-CoV-2 S1 RBD	50 - 200%	70-130%	< 20%	$\pm 25\%$	0.80 - 1.2

### **Additional Comments:**

Functional testing was executed using SARS-CoV-2 Plate 17 (Z0057190), SULFO-TAG Anti-Human IgG Antibody (D00V0025), Reference Standard 1 (A0080286), and Serology Controls (A00C0825, A00C0826, A00C0827).

All kit components were manufactured and tested according to MSD documents. The lots listed in the Kit Components table meet MSD's specifications.

#### Statement:

The above product is intended for Research Use Only. Not for use in Diagnostic Procedures.

	Name	Function	Signature	Date
Review/Approval	Karen Hamilla	Quality	Kann Hamille	20 JUN 2022